Thermo Fisher Scientific Inc. (TMO) Financials
PeriodQ2 FY2026
Published
Thermo Fisher Scientific reported $11.99 billion in revenue for Q2 FY2026, the quarter ended June 27, 2026, up 10.5% from a year earlier, with net income of $1.74 billion and diluted earnings per share of $4.68. Operating income was $2.09 billion, up 13.8%, and management described customer activity strengthening across its pharmaceutical, biotech, academic, government, industrial and diagnostics end markets; the revenue increase was split roughly evenly between organic growth and acquisitions, with a smaller contribution from currency translation. Total debt stood at $42.55 billion at quarter end, reflecting the March 2026 purchase of clinical trial data provider Clario, which also raised goodwill and drew down cash.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $11,994,000,000 | up 10.5% |
| Net income | $1,736,000,000 | up 7.4% |
| Diluted EPS | $4.68 | up 9.3% |
| Operating income | $2,087,000,000 | up 13.8% |
| Total debt | $42,549,000,000 |
Company details
| Name | Thermo Fisher Scientific Inc. |
|---|---|
| Ticker | TMO |
| CIK | 0000097745 |
| Exchange | NYSE |
| State | Massachusetts |
| Incorporation | Delaware |
| SIC | 3829 |
| Office | Industrial Applications and Services |
| Industry | Measuring & Controlling Devices, NEC |
| Latest period covered | Q2 FY2026, ended 2026-06-27, 10-Q, accession 0000097745-26-000144 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-10-30 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Thermo Fisher Scientific Q2 FY2026
How much revenue did Thermo Fisher Scientific report in Q2 FY2026?
Thermo Fisher Scientific reported $11.99 billion in revenue for Q2 FY2026, the quarter ended June 27, 2026. That is up 10.5% from $10.86 billion in the same quarter a year earlier, with roughly half of the increase coming from acquisitions rather than organic growth.
What was Thermo Fisher Scientific's earnings per share in Q2 FY2026?
Thermo Fisher Scientific reported diluted earnings per share of $4.68 for Q2 FY2026, up 9.3% from $4.28 a year earlier. Net income attributable to shareholders was $1.74 billion, up 7.4%.
Is Thermo Fisher Scientific's profitability improving?
Thermo Fisher Scientific's operating income was $2.09 billion in Q2 FY2026, up 13.8% from $1.83 billion a year earlier. Operating profit grew faster than revenue, which was up 10.5%. The company attributed the improvement to productivity gains, partly offset by unfavorable business mix.
How much debt does Thermo Fisher Scientific have?
Thermo Fisher Scientific carried $42.55 billion of total debt at June 27, 2026, including short term borrowings and current maturities. The company funded its March 2026 acquisition of Clario with cash on hand and new borrowing, and net interest expense in Q2 FY2026 was close to double the year-ago level.
Where can I get Thermo Fisher Scientific Inc. (TMO) financial data in machine-readable form?
Ticker Scout publishes Thermo Fisher Scientific Inc.'s financial statements as JSON at https://tickerscout.ai/tmo/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/tmo/narrative.md and https://tickerscout.ai/tmo/events.md. Thermo Fisher Scientific Inc.'s SEC CIK is 0000097745. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Thermo Fisher Scientific Inc. (TMO) next file with the SEC?
Thermo Fisher Scientific Inc. (TMO) is expected to file its next Form 10-Q with the SEC on or around October 30, 2026. That date is a projection rather than a company-announced date: it is derived from Thermo Fisher Scientific Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-27, SEC accession 0000097745-26-000144.
Related companies
How this page was built
This page was built from Thermo Fisher Scientific Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names five such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.